Ignite Creation Date:
2024-05-05 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00034879
Status:
COMPLETED
Last Update Posted:
2013-01-04
First Post:
2002-05-02
Brief Title:
Iressa Expanded Access Program EAP
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
An Expanded Access Clinical Program With ZD1839 IRESSA for Patients With Advanced Non-small Cell Lung Cancer NSCLC
Status:
COMPLETED
Status Verified Date:
2013-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
True
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A program for patients with non small cell lung cancer who may benefit from Iressa but cannot enter another clinical trial due to them not being eligible or for whom no trials are available
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None